Gilberto Lopes, MD
Results from the phase III KEYNOTE-042 trial demonstrated an improvement in overall survival (OS) with single-agent pembrolizumab (Keytruda) versus chemotherapy as a frontline treatment for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) and a PD-L1 expression level ≥1%, emphasizing immunotherapy’s role in the treatment armamentarium.
, Lopes, a medical oncologist at Sylvester Comprehensive Cancer Center, University of Miami Health System, discussed the KEYNOTE-042 results and ongoing developments with immunotherapy in NSCLC.
OncLive: What was the rationale and background of the KEYNOTE-042 trial?
: The way we treat lung cancer has changed markedly over the last few years. Some days, it feels like it's changing hour to hour. We have developed new targeted agents for patients with EGFR
mutations and ALK
translocations, as well as for those with other genetic changes. Immunotherapies have become part of our standard armamentarium. Pembrolizumab, in particular, is a PD-1 inhibitor that has been tested in a number of different clinical scenarios.
... to read the full story